

Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for dialysis, a blood-filtering therapy replacing vital kidney functions for patients suffering from chronic kidney failure. Through its network of around 3,200 dialysis clinics in more than 40 countries, Fresenius Medical Care provides dialysis treatments to around 262,000 patients. With more than 40 production sites around the globe, the company is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Strategy

Our long-term strategy aims at sustainably increasing shareholder value. We focus our business activities on our patients' health and hence on the quality of treatment with the objective of improving their quality of life and raising their life expectancy.

As our previous growth strategy GOAL 13 comes to a close in 2013, we intend to set new goals in the current financial year that will allow us to maintain our outstanding market position and to be successful in the dialysis market. Basically we will continue along our growth paths in the future:

- Organic growth through expansion of our clinic network, initiation of innovative dialysis products and comprehensive treatment concepts,
- acquisitions, with focus on particularly attractive regions,
- horizontal expansion and a boosted activity in home therapies


Key figures - summary first quarter 2013

Net revenue	\$ 3,464 million	+7%
Operating income (EBIT)	\$ 493 million	-2%
Net income ¹	\$ 225 million	-39%
Earnings per share	\$ 0.74	-40%
Total assets ²	\$ 22,140 million	
Operating cash flow	\$ 315 million	

Goals for 2013

Net revenue	> \$14.6 billion
Net income ¹	\$1.1 billion – \$1.2 billion
Leverage ratio (Debt/EBITDA)	≤ 3.0
Capital expenditures	~ \$700 million
Acquisitions	~ \$300 million

Revenue first quarter 2013 per region (US\$ 3,464 m)



Management Board

- Rice Powell (Chairman)
- Michael Brosnan
- Roberto Fusté
- Dr. Emanuele Gatti
- Ron Kuerbitz
- Dr. Rainer Runte
- Dr. Olaf Schermeier
- Kent Wanzek

¹ attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
² as of March 31, 2013

Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- Rolf A. Classon
- William P. Johnston
- Prof. Dr. Bernd Fahrholz



Share Profile – Key Data

Ticker Symbols	Ordinary shares	Preference shares
Frankfurt Stock Exchange	FME	FME3
New York Stock Exchange (NYSE)	FMS	FMS/P
Reuters: XETRA / Frankfurt Stock Exchange	FMEG.DE / FMEG.F	FMEG_p.DE / FMEG_p.F
Bloomberg	FME GY	FME3 GY
Security Identification Numbers		
WKN	578 580	578 583
ISIN	DE 0005785802	DE 0005785836
CUSIP No. (NYSE)	358029106	358029205

Financing Instruments and Maturity Profile

	Amount in million	Coupon %	Maturity
Credit Agreement Revolver	~\$ 1,250		October 30, 2017
Credit Agreement Term Loan A	\$ 2,600 ¹		October 30, 2017
Senior Notes 2010 - 2016	€ 250	5.50%	July 15, 2016
Senior Notes 2011 - 2016	€ 100	3-month-Euribor +3.50%	Oct. 15, 2016
Senior Notes 2007 - 2017	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2018	\$ 400	6.50%	September 15, 2018
Senior Notes 2011 - 2018	€ 400	6.50%	September 15, 2018
Senior Notes 2012 - 2019	\$ 800	5.625%	July 31, 2019
Senior Notes 2012 - 2019	€ 250	5.25%	July 31, 2019
Senior Notes 2011 - 2021	\$ 650	5.75%	February 15, 2021
Senior Notes 2011 - 2021	€ 300	5.25%	February 15, 2021
Senior Notes 2012 - 2022	\$ 700	5.875%	January 31, 2022
Notes (Schuldscheindarlehen) 2009 - 2014	€ 45 ¹		October 27, 2014
Accounts Receivable Facility	\$ 800		July 31, 2014

Share price - last 12 months (in €)




Financial Calendar

Event	Date
Report on first quarter 2013:	
Quarterly Report:	May 31, 2013
Annual General Meeting 2013:	May 16, 2013
Payment of dividend²:	May 17, 2013
Report on second quarter :	July 30, 2013
Report on Third Quarter 2013:	November 5, 2013

Capital Structure

Overview



Data as per April 30, 2013

Contacts

Fresenius Medical Care AG & Co. KGaA
Investor Relations & Corporate Communications
Else-Kröner-Straße 1 61352 Bad Homburg

Oliver Maier P: +49(0)6172-609-2525
Senior Vice President, F: +49(0)6172-609-2301
Head of IR & CC

Gerrit Jost P: +49(0)6172-609-5216
Vice President

North America
Terry L. Morris P: +1-800-948-2538
Vice President F: +1-615-345-5605

¹ at the beginning before amortisation

² Subject to the approval of the Annual General Meeting